Reminder for Gossamer Bio Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to apply as lead plaintiffs by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on the investors.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided false and misleading statements regarding its Phase 3 PROSERA study, leading to investor losses when the true information was revealed, highlighting significant flaws in the company's study design.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company, demonstrating its leadership in the field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.370
Low
10.00
Averages
12.33
High
15.00
Current: 0.370
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to apply as lead plaintiffs by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on the investors.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided false and misleading statements regarding its Phase 3 PROSERA study, leading to investor losses when the true information was revealed, highlighting significant flaws in the company's study design.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company, demonstrating its leadership in the field.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also threatens the company's listing status on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, which could have significant implications for the company's future legal liabilities.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to file claims, reflecting the market's heightened uncertainty regarding Gossamer's future prospects, potentially leading to further investor withdrawals.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, to apply as lead plaintiff.
- False Information Allegations: The lawsuit alleges that Gossamer provided misleading information regarding its Phase 3 PROSERA study while concealing adverse facts about the trial design, particularly concerning the placebo response, leading shareholders to buy securities at artificially inflated prices.
- Investor Losses: Due to Gossamer's false statements, investors purchased shares at inflated prices, resulting in potential financial losses, highlighting significant deficiencies in the company's transparency and compliance practices.
- Legal Consultation Opportunity: Bragar Eagel & Squire offers no-cost legal consultations, encouraging affected investors to contact the firm to understand their legal rights and potential claims, demonstrating a commitment to protecting investor interests.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose the true conditions of Latin American patients, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent activities, with investors needing to file by June 1, 2026, facing risks of misleading financial results.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is accused of overselling its projected book-to-bill ratio for Q4 2025, with a lead plaintiff deadline of June 5, 2026, potentially indicating a weak business environment.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact their firm to understand their legal rights and ensure protection in the class actions.
See More
Gossamer Bio Faces Class Action Lawsuit Following Trial Failure
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, covering the period from June 16, 2025, to February 20, 2026, which has led to significant investor losses.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by 80%, reflecting not only the market's pessimistic outlook on its future prospects but also prompting investigations by shareholder rights firms like Hagens Berman for potential violations of federal securities laws.
- Trial Design Controversy: The lawsuit focuses on Gossamer's disclosures regarding the PROSERA trial design, including patient recruitment protocols and site monitoring, alleging that the company misled investors by assuring them of positive outcomes despite being aware of design issues.
- Nasdaq Compliance Risk: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, further exacerbating investor concerns regarding the company's compliance and future viability.
See More
Faruqi & Faruqi Investigates Gossamer Bio Investor Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Gossamer Bio, Inc. for potential claims related to securities purchased between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Claims Deadline: Investors must contact Faruq & Faruq by June 1, 2026, to seek lead plaintiff status in a federal securities class action, which could significantly impact their legal options and rights.
- Investor Rights Protection: Partner Josh Wilson encourages affected investors to reach out directly to discuss their legal rights, demonstrating a commitment to protecting investor interests.
- Market Reaction Anticipation: The initiation of the legal investigation may negatively impact Gossamer's stock price, prompting investors to closely monitor developments to assess potential risks.
See More
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to apply as lead plaintiffs by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden on the investors.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided false and misleading statements regarding its Phase 3 PROSERA study, leading to investor losses when the true information was revealed, highlighting significant flaws in the company's study design.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company, demonstrating its leadership in the field.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: The stock price of Gossamer plummeted by 80% after the trial results failed to show statistical significance, which not only undermines investor confidence but also threatens the company's listing status on Nasdaq due to minimum bid price requirements.
- Legal Investigation: Hagens Berman has initiated an investigation into whether Gossamer violated federal securities laws, particularly regarding disclosures about the PROSERA trial design, which could have significant implications for the company's future legal liabilities.
- Investor Losses: The lawsuit encourages investors who suffered substantial losses during the class period to file claims, reflecting the market's heightened uncertainty regarding Gossamer's future prospects, potentially leading to further investor withdrawals.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, to apply as lead plaintiff.
- False Information Allegations: The lawsuit alleges that Gossamer provided misleading information regarding its Phase 3 PROSERA study while concealing adverse facts about the trial design, particularly concerning the placebo response, leading shareholders to buy securities at artificially inflated prices.
- Investor Losses: Due to Gossamer's false statements, investors purchased shares at inflated prices, resulting in potential financial losses, highlighting significant deficiencies in the company's transparency and compliance practices.
- Legal Consultation Opportunity: Bragar Eagel & Squire offers no-cost legal consultations, encouraging affected investors to contact the firm to understand their legal rights and potential claims, demonstrating a commitment to protecting investor interests.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose the true conditions of Latin American patients, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent activities, with investors needing to file by June 1, 2026, facing risks of misleading financial results.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is accused of overselling its projected book-to-bill ratio for Q4 2025, with a lead plaintiff deadline of June 5, 2026, potentially indicating a weak business environment.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact their firm to understand their legal rights and ensure protection in the class actions.
See More
Gossamer Bio Faces Class Action Lawsuit Following Trial Failure
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, covering the period from June 16, 2025, to February 20, 2026, which has led to significant investor losses.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by 80%, reflecting not only the market's pessimistic outlook on its future prospects but also prompting investigations by shareholder rights firms like Hagens Berman for potential violations of federal securities laws.
- Trial Design Controversy: The lawsuit focuses on Gossamer's disclosures regarding the PROSERA trial design, including patient recruitment protocols and site monitoring, alleging that the company misled investors by assuring them of positive outcomes despite being aware of design issues.
- Nasdaq Compliance Risk: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, further exacerbating investor concerns regarding the company's compliance and future viability.
See More
Faruqi & Faruqi Investigates Gossamer Bio Investor Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Gossamer Bio, Inc. for potential claims related to securities purchased between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Claims Deadline: Investors must contact Faruq & Faruq by June 1, 2026, to seek lead plaintiff status in a federal securities class action, which could significantly impact their legal options and rights.
- Investor Rights Protection: Partner Josh Wilson encourages affected investors to reach out directly to discuss their legal rights, demonstrating a commitment to protecting investor interests.
- Market Reaction Anticipation: The initiation of the legal investigation may negatively impact Gossamer's stock price, prompting investors to closely monitor developments to assess potential risks.
See More
